Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

Andrea De Luca, Mr Jordan, De Bennett, Ma Wainberg, D Havlir, S Hammer, C Yang, L Morris, M Peeters, Am Wensing, N Parkin, Jb Nachega, A Phillips, E Geng, A Calmy, E Raizes, P Sandstrom, Cp Archibald, J Perriëns, Cm McclureSy Hong, Jh Mcmahon, N Dedes, D Sutherland, S. Bertagnolio

Research output: Contribution to journalArticle

47 Citations (Scopus)


The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
Original languageEnglish
Pages (from-to)S245-S245-9
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume54 Suppl 4
Publication statusPublished - 2012


  • Anti-Retroviral Agents
  • Developing Countries
  • Drug Resistance, Viral
  • HIV Infections
  • Health Policy
  • Health Surveys
  • Humans
  • World Health
  • World Health Organization


Dive into the research topics of 'Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011'. Together they form a unique fingerprint.

Cite this